Section Arrow
STTK.NASDAQ
- Shattuck Labs
Quotes are at least 15-min delayed:2025/07/21 06:38 EDT
Pre Market
Last
 --
-- (--)
Bid
0.8092
Ask
0.8392
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 0.8092
+0.0642 (+8.62%)
Day High 
0.8223 
Prev. Close
0.745 
1-M High
1.14 
Volume 
129.34K 
Bid
0.8092
Ask
0.8392
Day Low
0.7399 
Open
0.7399 
1-M Low
0.7301 
Market Cap 
35.69M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.8 
20-SMA 0.86 
50-SMA 0.97 
52-W High 4.69 
52-W Low 0.69215 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.39/-0.98
Enterprise Value
38.19M
Balance Sheet
Book Value Per Share
1.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.72M
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.155 -0.92 -6.54%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.2 +0.36 +6.16%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.08 +0.16 +2.70%
Quotes are at least 15-min delayed:2025/07/21 06:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325,which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.